[Protective effect of Danzhi-xiaoyao San on rat brain energy or material metabolism (correction of matebolism) dealt with D-galactose].
OBJECTIVE
To research the mechanism of Danzhi-xiaoyao San (DZXYS) for treating Alzheimer's disease model of rats dealt with D-galactose.


METHODS
An Alzheimer's disease-like model of rats has been set up with sc. D-galactose 150.0 mg kg-1 D-1 x 49 d. Comparing with Acricept in 0.54 mg kg-1 D-1 dosage as a positive control drug, DZXYS in 12.636 g kg-1 D-1 x 49 d dosage has orally been administrated orally to treat the injury in the Alzheimer's disease-like model of rats. The energy charge in the cerebral tissues had been detested with waters liquid chromatography; the protein content and DNA content in the cerebral tissues had been detested with ultraviolet assay, the relative content of aldose reductase-mRNA is detested with RT-PCR. The difference was analyzed between the control rats without D-galactose, the model rats dealt with D-galactose, the model rats treated with Aricept and the model rats treated with DZXYS, it is significant as P<0.05.


RESULTS
1) DZXYS can not affect the energy charge in their cerebral tissues. 2) DZXYS can increase the protein content from 0.3139 +/- 0.019468 to 0.3213 +/- 0.015528 (ni=10, P>0.05) in their cerebral tissues. 3) DZXYS can increase the total DNA content from 1.093 +/- 0.267 to 1.488 +/- 0.341 (ni=10, P<0.01) in their cerebral tissues. 4) DZXYS can increase the content of AR-mRNA in their cerebral tissue from 0.732 +/- 0.159 to 1.418 +/- 0.277 (ni=5, P<0.01).


CONCLUSIONS
It suggests that DZXYS could be effective in human Alzheimer's disease for its stabling gene expression, maintaining protein characteristics, recovering signal transduction in the Alzheimer's disease-like model rats dealt with D-galactose.
Cai
Da-yong
DY
Beijing University of Traditional Chinese Medicine, Beijing, China. beijingcdy@yeah.net
Chen
Jin-xing
JX
Zhang
Wei
W
Wang
Xue
X
Sun
Li-ping
LP
Zhang
Jia-jun
JJ
Huang
Qi-fu
QF
D000449:Aldehyde Reductase / Q000378:metabolism; D000544:Alzheimer Disease; D000818:Animals; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D002800:Cholinesterase Inhibitors / Q000494:pharmacology*; D004247:DNA / Q000378:metabolism; D004195:Disease Models, Animal; D000077265:Donepezil; D004365:Drugs, Chinese Herbal / Q000494:pharmacology*; D005690:Galactose; D007189:Indans / Q000494:pharmacology*; D018697:Nootropic Agents / Q000494:pharmacology*; D010880:Piperidines / Q000494:pharmacology*; D011506:Proteins / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar
D002800:Cholinesterase Inhibitors; D004365:Drugs, Chinese Herbal; D007189:Indans; D018697:Nootropic Agents; D010880:Piperidines; D011506:Proteins; D012333:RNA, Messenger; D000077265:Donepezil; D004247:DNA; D000449:Aldehyde Reductase; D005690:Galactose